MSH2 and central nervous system cancer: The absence of MSI in the MSH2 mutated meningioma of our series indicates that, in meningiomas, the immunohistochemical loss of MMR proteins is not a good alternative to MSI testing and should not be used to select patients for treatment with immune check-point inhibitors, as already suggested in gliomas [40].